-+ 0.00%
-+ 0.00%
-+ 0.00%

Genfit plans Phase 2a nangibotide trial in acute-on-chronic liver failure by end-2026

PUBT·11/09/2026 06:30:46
Listen to the news
Genfit plans Phase 2a nangibotide trial in acute-on-chronic liver failure by end-2026
  • Genfit presented prior clinical data supporting nangibotide’s development for acute-on-chronic liver failure at AASLD’s Liver Meeting on November 8, 2026.
  • Across 416 exposed subjects, nangibotide’s safety profile was similar to placebo, with no safety signal identified.
  • Prior trials showed efficacy signals in a septic shock subgroup, alongside improved clinical status and lower mortality in severe COVID-19 patients.
  • The UPWARD Phase 2a trial is expected to begin by year-end 2026, subject to regulatory approval, with initial data expected in second-half 2027.
  • The placebo-controlled trial will primarily assess safety in patients with grade 2 acute-on-chronic liver failure and bacterial infection.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090130OMX_____CNEWS_EN_GNW1001302440_en) on November 09, 2026, and is solely responsible for the information contained therein.